CoChat

Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions

Open access

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; none of the 132 sources its claims cite is checked for support yet.

Abstract

The global prevalence of early-onset type 2 diabetes (EOT2D) is rising rapidly. Adults with EOT2D represent a high-risk population characterised by increased rates of microvascular and macrovascular complications, adverse psychological wellbeing and psychiatric comorbidities such as depression, and premature mortality compared to those with later-onset type 2 diabetes mellitus. This emerging population faces unique challenges, including high levels of diabetes-related stigma, clinical inertia, and competing life demands, such as starting a family. This review synthesises current evidence on the clinical management of EOT2D. Key therapeutic targets include weight reduction, preservation of β-cell function, cardiometabolic risk management, and psychological support. Overall, there are few randomized controlled trials (RCTs) undertaken specifically in adults with EOT2D. However, we summarise early data from the few RCTs that do report outcomes specific in young adults, with bariatric surgery, tirzepatide and intensive lifestyle interventions emerging as particularly effective treatments. There is a strong rationale that technology-based inventions and structured education programs may prove to be effective treatments but data from RCTs is lacking. We provide broad recommendations for future research and clinical practice based on the current evidence. In conclusion, substantial further research is required to inform tailored, evidence-based guidelines and improve long-term outcomes in this underserved population.

Overview

CoChat Summary

TL;DR

This narrative review summarizes current evidence on managing early-onset type 2 diabetes (EOT2D; diagnosis <40 years) in adults, a high-risk group with more complications, mental-health burden, and premature mortality than later-onset T2DM. It finds the strongest RCT/subanalysis signals for tirzepatide, bariatric surgery, and intensive lifestyle intervention, but concludes dedicated trials and tailored guidelines are urgently needed.

Key findings

  • EOT2D accounts for 15% to 20% of adults diagnosed with T2DM worldwide and is associated with higher microvascular and macrovascular disease, mortality, and psychological burden; 50% of adults with EOT2D report moderate-to-high diabetes distress versus 19% among those diagnosed with T2DM aged ≥60 years.
  • In the VERIFY subanalysis, adults with EOT2D (n=186; 9.3%) versus later-onset T2DM (n=1,815; 90.7%) had 5-year treatment failure (HbA1c ≥7.0%) of 50.5% with metformin plus vildagliptin versus 73.3% with metformin monotherapy in EOT2D; later-onset rates were 42.9% versus 61.0%. In the SURPASS post hoc analysis, SURPASS-2 included ~22.0% EOT2D (n=1,878); at 40 weeks, tirzepatide 15 mg reduced HbA1c by –2.6% versus –1.9% with semaglutide 1 mg, with 93.5% versus 75.3% achieving HbA1c <7.0%, and greater weight reduction (–14.0% vs. –5.4%).
  • Bariatric surgery observational data showed higher T2DM remission in EOT2D than later-onset T2DM at 1 year (56.9% vs. 50.2%) and 5 years (65.3% vs. 54.2%), plus greater 5-year weight loss (30.4% vs. 21.6%). The DIADEM-I intensive lifestyle RCT reported 12-month weight loss of –12.0 kg versus –4.0 kg with standard care and diabetes remission of 61.4% versus 11.6%; DiRECT remission fell from 46% at 1 year to 12.9% at 5 years (7% by intention-to-treat).
  • A CGM umbrella review found an HbA1c mean difference of –0.40% (95% CI, –0.54 to –0.25) in T2DM; one internet-based DSMES RCT in Chinese young adults (n=60 per group) showed greater 12-month HbA1c reduction (–1.8% vs. –1.2%, P<0.001) and remission (60% vs. 37%, P=0.03), but no RCTs specifically evaluated CGM, insulin pumps, or closed-loop therapy in adults with EOT2D.

Methods

  • Design: narrative review synthesizing current evidence on clinical management of EOT2D in adults; children and pregnancy management were excluded from scope.
  • Data/sample: cites RCTs, RCT subanalyses/post hoc analyses, observational studies, and systematic/umbrella reviews; no primary data collection. Dedicated EOT2D RCT evidence is limited to a few trials/subanalyses, including VERIFY, SURPASS, DIADEM-I, a small CGM-guided pilot, and an internet-based DSMES trial.
  • Main analysis: narrative synthesis and broad recommendations for practice and future research; no systematic search strategy, meta-analysis, or formal risk-of-bias assessment is described.

Limitations

  • Stated: few RCTs have been undertaken specifically in adults with EOT2D; young adults aged 18 to 39 years represent <5% of participants in prominent clinical trials; no specific clinical guidelines exist; long-term and hard clinical outcome data are lacking; the internet-based DSMES trial’s generalisability is limited to Chinese young adults, and sustainability questions remain.
  • Evident: as a narrative review, it does not report a systematic search, inclusion criteria, or quality appraisal, so selection and synthesis may be non-exhaustive.
  • Evident: many conclusions rely on subanalyses, post hoc analyses, or observational data rather than dedicated RCTs in EOT2D, and the authors avoid specific combination-therapy recommendations because direct comparisons are limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.4093/dmj.2025.0561

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Illustrates the broad range of complications and coexisting long-term conditions observed in individuals with early-onset type 2 diabetes (EOT2D). Conditions for which stronger evidence suggests increased severity or prevalence in EOT2D as compared to later-onset type 2 diabetes (LOT2D) are highlighted using a red ‘!’ and bold text.
Fig. 1. Illustrates the broad range of complications and coexisting long-term conditions observed in individuals with early-onset type 2 diabetes (EOT2D). Conditions for which stronger evidence suggests increased severity or prevalence in EOT2D as compared to later-onset type 2 diabetes (LOT2D) are highlighted using a red ‘!’ and bold text.CC BY-NC · PubMed Central
Fig. 2. Recommendations for future research in adults with early-onset type 2 diabetes (EOT2D). RCT, randomized controlled trial; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
Fig. 2. Recommendations for future research in adults with early-onset type 2 diabetes (EOT2D). RCT, randomized controlled trial; SGLT2i, sodium-glucose cotransporter 2 inhibitor.CC BY-NC · PubMed Central
Fig. 3. Recommendations for clinical practice for adults with early-onset type 2 diabetes (EOT2D). GLP-1, glucagon-like peptide-1.
Fig. 3. Recommendations for clinical practice for adults with early-onset type 2 diabetes (EOT2D). GLP-1, glucagon-like peptide-1.CC BY-NC · PubMed Central
Image 4
CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 6 Not valid · 74 Not checked · 33 Own results and interpretations

63 more claims

Create a free account to see all 113 claims and to verify the 124 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 14

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 116 references

Research works printed but not linked: 8

  1. IDF Diabetes Atlas 2021
  2. National diabetes statistics report
  3. Care processes and treatment targets
  4. 10.2337/figshare.13373708 · DOI · Paper page
  5. Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines, e563
  6. Type 1 diabetes in adults: diagnosis and management
  7. Type 2 diabetes in adults
  8. NHS Long Term Plan: Diabetes

Cited by

See all 11

Metadata

Authors
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J.
Affiliations
  • University of Leicester (GB)
  • University of Nottingham (GB)
Corresponding author
Davies, Melanie J.
Venue
Diabetes & Metabolism Journal
Published
2025-09-01
Volume
49
Issue
5
Pages
934-950
ISSN
  • 2233-6079 (ISSN-L)
  • 2233-6087
OpenAlex
W4414002032
Cited by
11
References
115
Citations by year
2026: 10 · 2025: 1
FWCI
0.94
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0/ (tdm)
Locations
  • Diabetes & Metabolism Journal (publishedVersion, cc-by-nc)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute for Health and Care Research (NIHR201165)
  • NIHR Leicester Biomedical Research Centre
  • Applied Research Collaboration East Midlands
  • Welcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme (223512/Z/21/Z)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
early-onset type 2 diabetes, young adults, diabetes management, bariatric surgery, tirzepatide, intensive lifestyle intervention, weight loss, beta-cell function, cardiometabolic risk, diabetes-related stigma, depression, psychological support, diabetes education, technology-based interventions, clinical inertia
MeSH terms
Adult, Diabetes Mellitus, Type 2, Humans, Life Style, Age of Onset, Bariatric Surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions. https://app.cochat.ai/papers/10.4093/dmj.2025.0561
The paper
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025). Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2025.0561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.